How "humane" is your endpoint?-refining the science-driven approach for termination of animal studies of chronic infection

PLoS Pathogens

Volumn 8, Issue 1, 2012, Pages

  Franco, Nuno H ^a   Correia Neves, Margarida ^b,c   Olsson, I Anna S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE COURSE; DISEASE SEVERITY; ETHICS; EXPERIMENTAL ANIMAL WELFARE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STANDARD; SURVIVAL TIME; TEMPERATURE; TUBERCULOSIS; WELLBEING;

ANIMAL EXPERIMENTATION; ANIMAL WELFARE; ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENDPOINT DETERMINATION; HUMANS; MICE; TUBERCULOSIS;

ANIMALIA;

EID: 84857461972     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002399     Document Type: Article

References (44)

1. Russell WMS, Burch RL, (1959) The principles of humane experimental technique London: Methuen & Co. Ltd.
2. ILAR, (2000) Humane endpoints for animals used in biomedical research and testing. ILAR Journal 41.
3. NRC, (2009) Recognition and alleviation of pain in laboratory animals. Washington (D.C.) National Academies Press.
4. Guittin P, Decelle T, (2002) Future improvements and implementation of animal care practices within the animal testing regulatory environment. ILAR J 43 Suppl pp. S80-S84.
5. OECD, (2000) Guidance document on the recognition, assessment and use of clinical signs as humane endpoints for experiemental animal used in safety evaluation. Paris Organisation for Economic Co-operation and Development.
6. Toth LA, (2000) Defining the moribund condition as an experimental endpoint for animal research. ILAR J 41: 72-79.
7. Chackerian AA, Behar SM, (2003) Susceptibility to Mycobacterium tuberculosis: lessons from inbred strains of mice. Tuberculosis (Edinburgh, Scotland) 83: 279-285.
8. Medina E, North RJ, (1998) Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93: 270-274.
9. Kondratieva E, Logunova N, Majorov K, Averbakh M, Apt A, (2010) Host genetics in granuloma formation: human-like lung pathology in mice with reciprocal genetic susceptibility to M. tuberculosis and M. avium. PLoS ONE 5: e10515 doi:10.1371/journal.pone.0010515.
10. Yuan R, Tsaih SW, Petkova SB, de Evsikova CM, Xing SQ, et al. (2009) Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 8: 277-287.
11. Srivastava S, Ayyagari A, Dhole TN, Krishnani N, Nyati KK, et al. (2008) Progression of chronic pulmonary tuberculosis in mice intravenously infected with ethambutol resistant Mycobacterium tuberculosis. Indian J Med Microbi 26: 342-348.
12. North RJ, Jung YJ, (2004) Immunity to tuberculosis. Annu Rev Immunol 22: 599-623.
13. Rook GAW, HernandezPando R, (1997) Pathogenetic role, in human and murine tuberculosis, of changes in the peripheral metabolism of glucocorticoids and antiglucocorticoids. Psychoneuroendocrino 22: S109-S113.
14. Bloch H, (1950) Studies on the virulence of tubercle bacilli- the relationship of the physiological state of the organisms to their pathogenicity. J Exp Med 92: 507-526.
15. Mench J, (1999) Defining endpoints: the role of animal care committees. In: Morton CFMHaDB, editors. Humane endpoints in animals experiments for biomedical research London Royal Society of Medicine Press pp. 133-138.
16. Morton DB, (2006) Ethical issues in the use of animal models of infection and some practical refinements. In: Friedman H, Specter S, Bendinelli M, editors. In vivo models of HIV disease and control pp. 405-424 Springer US.
17. Olfert ED, Godson DL, (2000) Humane endpoints for infectious disease animal models. ILAR J 41: 99-104.
18. Lyadova IV, Tsiganov EN, Kapina MA, Shepelkova GS, Sosunov VV, et al. (2010) In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs. PLoS ONE 5: e10469 doi:10.1371/journal.pone.0010469.
19. Nikonenko BV, Averbakh MM, Lavebratt C, Schurr E, Apt AS, (2000) Comparative analysis of mycobacterial infections in susceptible I/St and resistant A/Sn inbred mice. Tuber Lung Dis 80: 15-25.
20. Romano M, D'Souza S, Adnet P-Y, Laali R, Jurion F, et al. (2006) Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24: 3353.
21. Stewart GR, Newton SM, Wilkinson KA, Humphreys IR, Murphy HN, et al. (2005) The stress-responsive chaperone alpha-crystallin 2 is required for pathogenesis of Mycobacterium tuberculosis. Mol Microbiol 55: 1127-1137.
22. Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, et al. (2007) Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 56: 2557-2565.
23. Lavebratt C, Apt AS, Nikonenko BV, Schalling M, Schurr E, (1999) Severity of tuberculosis in mice is linked to distal chromosome 3 and proximal chromosome 9. J Infect Dis 180: 150-155.
24. Sánchez F, Radaeva TV, Nikonenko BV, Persson A-S, Sengul S, et al. (2003) Multigenic control of disease severity after virulent Mycobacterium tuberculosis infection in mice. Infect Immun 71: 126-131.
25. Nikonenko BV, Samala R, Einck L, Nacy CA, (2004) Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 4550-4555.
26. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, et al. (2007) A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178: 7450-7457.
27. Triccas JA, Shklovskaya E, Spratt J, Ryan AA, Palendira U, et al. (2007) Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect Immun 75: 5368-5375.
28. Urdahl KB, Liggitt D, Bevan MJ, (2003) CD8(+) T cells accumulate in the lungs of Mycobacterium tuberculosis-infected Kb-/-Db-/- mice, but provide minimal protection. J Immunol 170: 1987-1994.
29. Holscher C, Holscher A, Ruckerl D, Yoshimoto T, Yoshida H, et al. (2005) The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 174: 3534-3544.
30. Kapina MA, Shepelkova GS, Mischenko VV, Sayles P, Bogacheva P, et al. (2007) CD27(low) CD4 T lymphocytes that accumulate in the mouse lungs during mycobacterial infection differentiate from CD27(high) precursors in situ, produce IFN-gamma, and protect the host against tuberculosis infection. J Immunol 178: 976-985.
31. Kort WJ, Hekking-Weijma JM, Tenkate MT, Sorm V, VanStrik R, (1998) A microchip implant system as a method to determine body temperature of terminally ill rats and mice. Lab Anim 32: 260-269.
32. Soothill JS, Morton DB, Ahmad A, (1992) The HID50 (hypothermia-inducing dose 50): an alternative to the LD50 for measurement of bacterial virulence. Int J Exp Pathol 73: 95-98.
33. Wong JP, Saravolac EG, Clement JG, Nagata LP, (1997) Development of a murine hypothermia model for study of respiratory tract influenza virus infection. Lab Anim Sci 47: 143-147.
34. Bast DJ, Yue M, Chen X, Bell D, Dresser L, et al. (2004) Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. Antimicrob Agents Chemother 48: 3343-3348.
35. Warn PA, Brampton MW, Sharp A, Morrissey G, Steel N, et al. (2003) Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim 37: 126-131.
36. Vlach KD, Boles JW, Stiles BG, (2000) Telemetric evaluation of body temperature and physical activity as predictors of mortality in a murine model of staphylococcal enterotoxic shock. Comparative Med 50: 160-166.
37. Verhoeven D, Teijaro JR, Farber DL, (2009) Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology 390: 151-156.
38. Schaecher K, Kumar S, Yadava A, Vahey M, Ockenhouse CF, (2005) Genome-wide expression profiling in malaria infection reveals transcriptional changes associated with lethal and nonlethal outcomes. Infect Immun 73: 6091-6100.
39. Yu Y, Clippinger AJ, Alwine JC, (2011) Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection. Trends Microbiol 19: 360-367.
40. Beamer GL, Flaherty DK, Vesosky B, Turner J, (2008) Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol 15: 474-483.
41. Jamil B, Shahid F, Hasan Z, Nasir N, Razzaki T, et al. (2007) Interferon[gamma]/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. Tuberculosis 87: 279-287.
42. Millington KA, Innes JA, Hackforth S, Hinks TSC, Deeks JJ, et al. (2007) Dynamic relationship between IFN-γ and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 178: 5217-5226.
43. Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977.
44. Demers G, Griffin G, De Vroey G, Haywood JR, Zurlo J, et al. (2006) Harmonization of animal care and use guidance. Science 312: 700-701.